Support teaching, research, and patient care.
Dr. Ebel is the inaugural Chief of the Section of Hepatology and the Co-Director of the Abdominal Organ Transplant Center of Emphasis. Dr. Ebel's clinical and research interests lie at the intersection of the heart and the liver, specifically for Fontan associated liver disease and indications for combined heart-liver transplantation. She is the Director of the Alagille Syndrome Program at Stanford and supports a growing international referral program for patients with Alagille syndrome and their complex heart and liver needs.https://www.stanfordchildrens.org/en/service/alagille-syndromeDr. Ebel is the Director of Policy in the Office of Child Health Equity at Stanford and is committed to eliminating health disparities for children with liver disease on both an institutional and national level. She works to galvanize pediatric subspecialists to engage in health policy and health equity work to assure equal care for all children. Her current work centers on equitable access in living donor liver transplantation. https://tts.org/split-advocacyDr. Ebel most recently received early career investigator awards from the American Association for the Study of Liver Diseases (AASLD) and the International Pediatric Transplant Association (IPTA).She can be found on social media: @NoelleEbelMD (Twitter)
Current projects include: -indications for combined heart-liver transplantation-mitigating perioperative bleeding during cardiac surgery in children with Alagille syndrome-congenital heart disease and liver transplantation-subspecialty advocacy
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
This study is designed to assess whether the investigational drug maralixibat, is safe and
well tolerated in children <12 months of age with Alagille Syndrome [ALGS] or Progressive
Familial Intrahepatic Cholestasis [PFIC].
View full details
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
The goal of this interventional study is to test a hemostasis screening protocol and cardiac
peri-procedural and post-operative hemostasis pathway to improving bleeding complications and
improve patient survival for children with Alagille syndrome and complex cardiac conditions.
The main questions it aims to answer are:
- Are children with Alagille syndrome with cardiac anomalies more likely to have acquired
von Willebrand syndrome (a condition that causes increased bleeding)
- Does implementation of a novel screening protocol to detect pre-operative bleeding
conditions decrease intra-operative and/or post-operative bleeding complications and
- Does implementation of a novel screening protocol to detect and treat bleeding
conditions cause thrombotic complications?
Participants will undergo additional hematology and bleeding disorder screening prior to
cardiac surgery. They will additionally undergo a detailed family screening for a history of
bleeding by a genetic counselor.
Researchers will compare these findings with children who have similar complex cardiac
conditions requiring surgery, but who do not have Alagille syndrome to see if bleeding
conditions and complications are more or less common in children with Alagille syndrome.